Initiative with the Department of Clinical Neurosciences

The aim of this initiative is to identify core mechanisms of protein aggregation and spreading in neurodegeneration; and to apply that knowledge to first-in-human studies of putative new therapies using the most informative patients and sensitive outcome measures of efficacy.

The scientists involved from the LMB combine expertise in high-resolution structural biology, mechanisms of protein aggregation and inter-cellular transfer, and quality control processes in neurones and glia; research in the Department of Clinical Neurosciences focuses on the consequences of these events for mechanisms of neuronal and synaptic loss that lead to neurodegeneration, the development of novel therapies, and their evaluation in patients using sensitive clinical outcomes and studies of brain structure and function based on positron emission tomography and magnetic resonance imaging.